Navigation Links
Mr. Jean-Pierre Garnier Concludes his Mission at the Pierre Fabre Company
Date:6/28/2010

CASTRES, France, June 28, 2010 /PRNewswire/ -- Mr Jean-Pierre Garnier will step down on September 1st 2010, two years after having been appointed CEO of the Pierre Fabre Group.

"The Company is in excellent health, and is poised to experience a bright future ; I am glad to have contributed to its success and I take this opportunity to thank Mr. Pierre Fabre, visionary founder, for having entrusted me with this important mission".

Mr. Pierre Fabre thanked Mr Jean-Pierre Garnier for his "commitment and the excellent work performed" and stated that "his contribution over the past two years has been of the utmost benefit to the Company".

The new governance, which will continue in the spirit of the current organisation, will be announced in the near future.

    About Pierre Fabre group :

    The Pierre Fabre Group, the second largest independent French
    pharmaceutical company and leader in the field of in-pharmacy
    dermocosmetics, employs about 10,000 people worldwide, including 1,400 R&D
    staff, and generates a turnover of EUR 1.8 billion.

    In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to
    R&D in four priority therapeutic areas in public health: oncology, central
    nervous system, dermatology, cardio-vascular/metabolism.

    To learn more about Pierre Fabre, please refer to
    http://www.pierre-fabre.com.

    Press Contact :

    Djamila Hazene-Kedjem
    djamila.hazene.kedjem@pierre-fabre.com
    +33(0)1-49-10-81-72 / +33(6)89-45-87-95



'/>"/>
SOURCE Groupe Pierre Fabre
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
2. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
5. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
6. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
7. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
8. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
9. Indevus Announces Submission of New Drug Application
10. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
11. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... July 17, 2017  MedX Holdings, Inc., the manufacturer ... strengthening and rehabilitation equipment, today announced the national roll ... is considered the gold standard for the treatment of ... medical strengthening equipment. ... the physician or practice who prescribe the MedX Home ...
(Date:7/13/2017)... , July 13, 2017 RK Logistics Group, ... of Pharmacy certification for its Fremont, CA ... solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont Innovation ... to provide such a powerful resource to the hundreds of ...
(Date:7/11/2017)... 2017  Bayer has awarded grants totaling more than $2 ... its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians ... and Uniformed Services University of the Health Sciences ... Grant recipients were announced last night during a reception at ... Berlin, Germany . ...
Breaking Medicine Technology:
(Date:7/22/2017)... ... July 21, 2017 , ... Reassured For Life ( http://www.reassured.ca ), is now ... owner and licensed broker Nerissa McNaughton. “I launched this firm because I know talking ... a very necessary conversation. I make it easy. As a broker I have access ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... "As a ... a lot of pleural catheters available on the market," said an inventor from Center ... comfort and safety for the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER ...
(Date:7/21/2017)... ... 2017 , ... The Ellis Agency, an eastern Georgie provider of insurance management ... wide charity event with the goal of bringing in support for epilepsy patients in ... with epilepsy, recently launched a charity campaign of her own by donating her birthday ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... selected to renovate and improve the Ramsey County Medical Examiners Facility located in ... Hospital, the $2.5 million project is scheduled to start in late 2017/early 2018. ...
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed ... . The number of hospital acquisitions rose to 23 in the second quarter, up ... up 15% from the 20 announced deals in the year-ago second quarter. Only four ...
Breaking Medicine News(10 mins):